Viewing data from:

TIZANIDINE HYDROCHLORIDE

ANDA

TIZANIDINE HYDROCHLORIDE | A208187 | CADILA HEALTHCARE LTD

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ZANAFLEX(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 5 NDCs

Highest NADAC/Unit

$0.0332

per ea

Lowest NADAC/Unit

$0.0309

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
72578009710TIZANIDINE HCL 4 MG TABLET	$0.0332	EA	Generic	—	2026-06-17
72578009721TIZANIDINE HCL 4 MG TABLET	$0.0332	EA	Generic	—	2026-06-17
72578009776TIZANIDINE HCL 4 MG TABLET	$0.0332	EA	Generic	—	2026-06-17
72578009610TIZANIDINE HCL 2 MG TABLET	$0.0309	EA	Generic	—	2026-06-17
72578009621TIZANIDINE HCL 2 MG TABLET	$0.0309	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain9 active DMFs4 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDTIZANIDINE HYDROCHLORIDE USP

DMF 156992001

SUN PHARMACEUTICAL INDUSTRIES LTDTIZANIDINE HYDROCHLORIDE USP

DMF 157272001

TAPI NL BVTIZANIDINE HYDROCHLORIDE USP

DMF 158202002

MATRIX PHARMACORP PRIVATE LTDTIZANIDINE HYDROCHLORIDE USP

DMF 223542008

PH HEALTH LTDTIZANIDINE HYDROCHLORIDE, USP

DMF 281762014

SYMED LABS LTDTIZANIDINE HYDROCHLORIDE USP

DMF 339002019

ZYDUS LIFESCIENCES LTDTIZANIDINE HYDROCHLORIDE USP

DMF 349292020

DR REDDYS LABORATORIES LTDTIZANIDINE HYDROCHLORIDE USP (TZN-PROCESS)

DMF 414312025

AKTIN PHARMACEUTICALS CO LTDTIZANIDINE HYDROCHLORIDE

DMF 439322026

SANDOZ PHARMA LTDInactiveTIZANIDINE HYDROCHLORIDE

DMF 92421991

FARCHEMIA SRLInactiveTIZANIDINE HYDROCHLORIDE

DMF 155552001

HETERO DRUGS LTDInactiveTIZANIDINE HYDROCHLORIDE

DMF 157302001

APOTEX PHARMACHEM INDIA PVT LTDInactiveTIZANIDINE HYDROCHLORIDE USP

DMF 222822008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 2MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Mar 9, 2018

No patent or exclusivity listings for this strength.

#002 — EQ 4MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Mar 9, 2018